CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsLow earnings quality
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.08%
Annual Rate
CNY 0.01Paid annual
Payout Ratio
10.7%Sustainable
Last Ex-Dividend
Jun 17, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.92BCNY879.42M · vs all stocks (USD)
Trailing P/E
151.27xvs Biotechnology peers
Revenue (TTM)
949.94MCNY141.08M · vs all stocks (USD)
Profit Margin
4.53%vs Biotechnology peers
Beta
0.2150xvs all stocks
52-Week Change
28.13%vs all stocks
Market Capitalization
5.92BCNY879.42M · vs all stocks (USD)
Enterprise Value
6.42BCNY953.40M · vs all stocks (USD)
Trailing P/E
151.27xvs Biotechnology peers
Forward P/E
64.00xvs Biotechnology peers
Price to Sales (TTM)
6.76xvs Biotechnology peers
Price to Book (MRQ)
5.96xvs Biotechnology peers
Enterprise to Revenue
6.76xvs Biotechnology peers
Enterprise to EBITDA
113.83xvs Biotechnology peers
Gross Margin
28.45%vs Biotechnology peers
Profit Margin
4.53%vs Biotechnology peers
Operating Margin
8.11%vs Biotechnology peers
Return on Assets (TTM)
1.20%vs Biotechnology peers
Return on Equity (TTM)
4.19%vs Biotechnology peers
Revenue (TTM)
949.94MCNY141.08M · vs all stocks (USD)
Revenue per Share (TTM)
2.47CNYUpdated Aug 19, 2026Quarterly Revenue Growth
58.50%vs Biotechnology peers
Gross Profit (TTM)
252.37MCNY37.48M · vs all stocks (USD)
EBITDA (TTM)
74.45MCNY11.06M · vs all stocks (USD)
Net Income (TTM)
43.05MCNY6.39M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
322.00%vs Biotechnology peers
Operating Cash Flow (TTM)
67.05MCNY9.96M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
36.74MCNY5.46M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0130CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.08%vs all stocks
Payout Ratio
10.70%vs Biotechnology peers
Minority Interest (Equity)
34.25MCNYFY2025 · Dec 31, 2025Revenue
868.64MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
633.03MCNYFY2025 · Dec 31, 2025Gross Profit
235.62MCNYFY2025 · Dec 31, 2025Operating Income
60.05MCNY8.92M · vs all stocks (USD)
Pre-tax Income
30.06MCNYFY2025 · Dec 31, 2025Income Tax Expense
-2.85MCNYFY2025 · Dec 31, 2025Net Income
32.91MCNYFY2025 · Dec 31, 2025EBIT
31.73MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
88.50MCNYFY2025 · Dec 31, 2025Research & Development
57.50MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
32.69MCNYFY2025 · Dec 31, 2025Other Operating Expenses
7.57MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
830.75KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.68MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0794CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0794CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
384.06MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
384.06MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
32.91MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-2.42MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-93.03MCNYFY2025 · Dec 31, 2025Free Cash Flow
-111.74MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
325.43MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
32.91MCNYFY2025 · Dec 31, 2025Other Non-cash Items
8.85MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-80.70MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-54.09MCNYFY2025 · Dec 31, 2025Capital Expenditures
-18.70MCNYFY2025 · Dec 31, 2025Purchase of Investments
-7.58MCNYFY2025 · Dec 31, 2025Sale of Investments
11.38MCNYFY2025 · Dec 31, 2025Other Investing Activity
-31.50MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-46.40MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
44.69MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-45.51MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-5.92MCNYFY2025 · Dec 31, 2025Other Financing Charges
23.87MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
17.13MCNYFY2025 · Dec 31, 2025Shares Outstanding
385.86MSharesUpdated Aug 19, 2026Float Shares
245.74MSharesUpdated Aug 19, 2026% Held by Insiders
40.14%vs all stocks
% Held by Institutions
0.27%vs all stocks
Total Cash (MRQ)
393.85MCNY58.49M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.03CNYUpdated Aug 19, 2026Total Debt (MRQ)
41.91MCNY6.22M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0380xvs Biotechnology peers
Current Ratio (MRQ)
1.92xvs Biotechnology peers
Book Value per Share (MRQ)
2.79CNYUpdated Aug 19, 2026Total Assets
1.63BCNY242.00M · vs all stocks (USD)
Total Current Assets
960.72MCNYFY2025 · Dec 31, 2025Total Liabilities
569.88MCNYFY2025 · Dec 31, 2025Total Non-current Assets
668.70MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
44.56MCNYFY2025 · Dec 31, 2025Total Current Liabilities
525.33MCNYFY2025 · Dec 31, 2025Cash
325.45MCNYFY2025 · Dec 31, 2025Cash Equivalents
757.49KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
326.21MCNYFY2025 · Dec 31, 2025Other Short-term Investments
55.37MCNYFY2025 · Dec 31, 2025Accounts Receivable
187.53MCNYFY2025 · Dec 31, 2025Inventory
228.04MCNYFY2025 · Dec 31, 2025Accounts Payable
176.58MCNYFY2025 · Dec 31, 2025Short-term Debt
8.05MCNYFY2025 · Dec 31, 2025Other Current Liabilities
9.91MCNYFY2025 · Dec 31, 2025Long-term Debt
35.75MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
377.00KCNYFY2025 · Dec 31, 2025Common Stock (Book)
385.73MCNYFY2025 · Dec 31, 2025Retained Earnings
228.25MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.06BCNY157.36M · vs all stocks (USD)
Treasury Stock
17.66MCNYFY2025 · Dec 31, 202552-Week Low
8.15CNYUpdated Aug 19, 202652-Week High
17.99CNYUpdated Aug 19, 202652-Week Change
28.13%vs all stocks
Beta
0.2150xvs all stocks
50-Day MA
9.82CNYUpdated Aug 19, 2026200-Day MA
10.12CNYUpdated Aug 19, 2026Avg 10-Day Volume
58.25MSharesUpdated Aug 19, 2026Avg 30-Day Volume
35.75MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.1100CNYUpdated Aug 19, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -1.87
Altman Z-Score 7.35: safe zoneNotable
Altman Z-Score: 7.35
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Theravance Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Amphastar Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
InMode Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Corcept Therapeutics Incorporated
4 interpretationsMinimal Tax and Interest DragRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital Elevated
Minda Corporation Ltd.
3 interpretationsRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital Elevated
Acro Biosystems Co., Ltd.
3 interpretationsMinimal Tax and Interest DragRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income Growth